{"classes":[{"categories":[{"measurements":[{"comment":"MTD/RP2D not achieved in this study","groupId":"OG000","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"Based on review of all data, including safety, tolerability, PK, antitumor activity, and PD effects","groups":[{"description":"SL-279252 received in Schedule 1 or Schedule 2","id":"OG000","title":"SL-279252"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Approximately 32 months","title":"Recommended Phase 2 Dose for SL-279252","type":"SECONDARY","unitOfMeasure":"mg/kg"}